Niagen Bioscience, Inc. — Filing Summary
Issuer identification: The supplied filing is ChromaDex Corporation’s Form 10-Q (Nasdaq: CDXC), not a filing under the name Niagen Bioscience, Inc. Niagen is the company’s ingredient and product brand. The report covers the quarter and six months ended June 30, 2023; financial statements are unaudited.
Business context and reporting period
ChromaDex is a bioscience company focused on healthy aging and nicotinamide riboside (NR), marketed as Niagen. Its segments are Consumer Products, Ingredients, and Analytical Reference Standards and Services. Tru Niagen is its flagship consumer product.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net sales | $20.3 million | $16.7 million | $42.9 million | $34.0 million |
| Gross profit | $12.4 million | $10.0 million | $25.9 million | $20.6 million |
| Gross margin | 60.8% | 60.0% | 60.3% | 60.5% |
| Operating expenses | $14.7 million | $16.4 million | $30.2 million | $34.7 million |
| Operating loss | $2.3 million | $6.4 million | $4.3 million | $14.1 million |
| Net loss | $2.2 million | $6.4 million | $4.1 million | $14.1 million |
| Loss per share | $0.03 | $0.09 | $0.05 | $0.21 |
Six-month operating cash flow was positive $6.1 million, versus negative $11.0 million in the prior-year period. The improvement reflected lower net loss and better inventory cash management. Investing cash outflow was $0.1 million; financing cash outflow was nominal.
At June 30, 2023, cash and cash equivalents were $26.4 million, including $26.3 million unrestricted. Current assets were $46.4 million and current liabilities $19.1 million. Total liabilities were $26.0 million; the filing reports no outstanding borrowings under its bank line. The line’s stated maximum is $10.0 million, with $4.9 million of borrowing availability under its terms. Total stockholders’ equity was $27.2 million.
Changes versus prior comparable periods
- Q2 sales increased 21%; first-half sales increased 26%. Consumer Products sales grew 16% and 17%, respectively, while Ingredients sales grew 85% and 136%. Analytical Reference Standards and Services sales declined 3% and 7%.
- Growth came principally from Tru Niagen consumer sales and Niagen ingredient demand. Management attributed consumer growth to higher A.S. Watson purchases and e-commerce performance, and ingredient growth to demand from existing and new partners.
- Operating losses narrowed substantially as gross profit rose and operating expenses fell. First-half sales and marketing expense declined $2.4 million; general and administrative expense declined $2.4 million, chiefly from lower legal costs and share-based compensation, partly offset by doubtful-receivable provisions.
- Trade receivables fell to $6.1 million from $8.5 million at year-end; inventories fell to $12.0 million from $14.7 million.
Outlook, risks, contingencies, and unusual items
- Outlook: No quantified revenue or earnings guidance is provided. Management expects e-commerce to be the primary catalyst for growth through 2023 and expects unrestricted cash plus cash generated from sales to cover obligations for at least twelve months from issuance. It may seek additional capital for longer-term plans.
- Liquidity qualification: Management identified recurring operating losses, prior negative operating cash flows, and inflationary pressures as conditions raising substantial doubt in its assessment. It nevertheless concluded that available cash and expected sales cash flows should be sufficient for at least the next twelve months. The $47.8 million ATM capacity remained available, but use is subject to contractual conditions and market conditions and may not provide dependable liquidity.
- Customer and credit exposure: A.S. Watson, a related party, accounted for 15.6% of first-half sales. About 79% of receivables were concentrated among three customers; A.S. Watson represented 45.3% of receivables. The company recorded $0.8 million of doubtful-receivable provision in the first half, primarily related to the Chapter 11 filing of iMedia Brands, a Tru Niagen sales channel.
- Commitments: The company reported $8.2 million of inventory purchase commitments and $4.5 million of future minimum lease payments. Operating lease liabilities totaled $3.9 million.
- Legal and intellectual-property matters: Litigation with Elysium remains ongoing. The Delaware patent case was affirmed against ChromaDex on appeal, and the company reported that Elysium sought attorneys’ fees and costs; ChromaDex stated it did not expect the decision to materially affect its NR business. Appeals and related proceedings remain relevant. The filing says the company cannot reasonably estimate a possible loss in the Elysium SDNY matter and recorded no accrual for it. A separate disputed $1.6 million sublicense-fee claim was not considered likely to be material by management.
- Regulatory matter: The company previously received FDA/FTC and FTC warning letters concerning COVID-related statements about NR research. It reported removing or addressing identified social-media content and did not expect the matter’s ultimate resolution to be material.
- Unusual items: The company received $0.9 million of Employee Retention Tax Credit proceeds during the first half; a further $0.9 million benefit remained on the balance sheet at June 30. The filing also reports a $29,000 opening retained-earnings adjustment on adoption of the expected-credit-loss standard.
- Other risks: Inflation may pressure costs and margins; the company relies on a limited number of suppliers, including an exclusive NR manufacturer. The China joint venture’s commercialization depends on regulatory “Blue Hat” registration, whose timing was uncertain. Management reported effective disclosure controls and no material second-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: this is ChromaDex Corporation’s 10-Q, while Niagen is a brand, not the registrant named on the filing.
- Track whether sales growth—particularly e-commerce, A.S. Watson, and Niagen ingredient demand—continues and whether customer concentration declines.
- Assess cash conversion and working-capital trends; first-half positive operating cash flow benefited from receivables and inventory movements and may fluctuate.
- Monitor the liquidity caveat, bank-line conditions, ATM availability and any need for potentially dilutive financing.
- Follow Elysium litigation, patent-related appeals and fee requests, and any change in the company’s loss estimates or accruals.
- Check progress toward China Blue Hat registration and the related potential payments and commercialization terms.